(1S,6R)-2-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]-2-azabicyclo[4.1.0]heptane-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,6R)-2-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]-2-azabicyclo[4.1.0]heptane-1-carboxylic acid
• 化学式: C₂₄H₂₀F₂N₆O₃
• 分子量: 478.5
• InChiKey: MMLNISRHBDETTL-MYYSRTQBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
  申请人：IRONWOOD PHARMACEUTICALS, INC.

  公开号：US20160324856A1

  公开（公告）日：2016-11-10

  The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising a sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a neuromuscular disorder associated with loss or alteration of function of nitric oxide synthase (NOS).
• sGC STIMULATORS
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：US20160347738A1

  公开（公告）日：2016-12-01

  Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
• [EN] SGC STIMULATORS<br/>[FR] STIMULATEURS DE SGC
  申请人：NAKAI TAKASHI

  公开号：WO2014144100A2

  公开（公告）日：2014-09-18

  Compounds of Formulae (I') and (I) are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
• [EN] USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS<br/>[FR] UTILISATION DE STIMULATEURS DE LA SGC POUR LE TRAITEMENT DE TROUBLES NEUROMUSCULAIRES
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2015106268A1

  公开（公告）日：2015-07-16

  The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising a sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a neuromuscular disorder associated with loss or alteration of function of nitric oxide synthase (NOS).